RESEARCHER PROFILE
Eduardo Alegría
← Back to Universidad Francisco de Vitoria
E
Universidad Francisco de Vitoria
Eduardo Alegría works in Diabetes, Cardiovascular Risks, and Lipoproteins, Lipoproteins and Cardiovascular Health, Blood Pressure and Hypertension Studies, Acute Myocardial Infarction Research, Cardiac Imaging and Diagnostics. Recorded institutional associations include Universidad Francisco de Vitoria.
96Publications
9,548Citations
32H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
ESC/EAS Guidelines for the management of dyslipidaemias
2011 · 3,531 citationsManagement of acute myocardial infarction in patients presenting with persistent ST-segment elevation
2008 · 2,310 citationsESC/EAS Guidelines for the management of dyslipidaemias
2011 · 709 citationsComparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation
2004 · 232 citationsESC/EAS Guidelines for the management of dyslipidaemias
2011 · 192 citationsEpidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model
2010 · 161 citationsPrevalencia del síndrome metabólico en población laboral española: registro MESYAS
2005 · 158 citationsESC/EAS Guidelines for the management of dyslipidaemias
2011 · 154 citationsAutologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up
2006 · 132 citationsPrevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en España. Estudio DYSIS-España
2011 · 99 citationsCurrent practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
2016 · 97 citationsComparison of Serum Lipid Values in Subjects With and Without the Metabolic Syndrome
2008 · 94 citationsUsefulness of Triglycerides-to–High-Density Lipoprotein Cholesterol Ratio for Predicting the First Coronary Event in Men
2009 · 90 citationsPrevalence of Metabolic Syndrome in the Spanish Working Population: MESYAS Registry
2005 · 87 citationsA review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy
2015 · 85 citationsTransplantation of Mesenchymal Stem Cells Exerts a Greater Long-Term Effect than Bone Marrow Mononuclear Cells in a Chronic Myocardial Infarction Model in Rat
2010 · 76 citationsGuías de práctica clínica de la Sociedad Española de Cardiología en pruebas de esfuerzo
2000 · 67 citationsRationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)
2021 · 67 citationsMortalidad a largo plazo y reingreso hospitalario tras infarto agudo de miocardio: un estudio de seguimiento de ocho años
2011 · 64 citationsGuía de la ESC/EAS sobre el manejo de las dislipemias
2011 · 63 citationsLong-Term Mortality and Hospital Readmission After Acute Myocardial Infarction: an Eight-Year Follow-Up Study
2012 · 61 citationsESC/EAS Guidelines for the Management of Dyslipidaemias
2013 · 60 citationsTendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014
2015 · 58 citationsEffect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
2005 · 50 citationsBlood Pressure and Lipid Goal Attainment in the Hypertensive Population in the Primary Care Setting in Spain
2007 · 47 citations
